Treatment of early-stage lung cancer detected by screening: Surgery or stereotactic ablative radiotherapy?

The Lancet Oncology

Volumn 14, Issue 7, 2013, Pages

  Senan, Suresh ^a   Paul, Marinus A ^a   Lagerwaard, Frank J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

BRONCHUS STENOSIS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; EARLY CANCER; FALSE POSITIVE RESULT; HUMAN; LUNG CANCER; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; OVERALL SURVIVAL; PATIENT DECISION MAKING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; RIB FRACTURE; STEREOTACTIC ABLATIVE RADIOTHERAPY; STEREOTACTIC TREATMENT; THORAX PAIN; TUMOR ABLATION; VIDEO ASSISTED THORACOSCOPIC SURGERY;

CATHETER ABLATION; EARLY DETECTION OF CANCER; HUMANS; LUNG NEOPLASMS; PNEUMONECTOMY; RADIOSURGERY;

EID: 84878364248     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70592-2     Document Type: Review

References (52)

1. Aberle D, Adams A, Berg C, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011, 365:395-409. for the National Lung Screening Trial Research Team.
2. Bach P, Mirkin J, Oliver T, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 2012, 307:2418-2429.
3. van Klaveren RJ, Oudkerk M, Prokop M, et al. Management of lung nodules detected by volume CT scanning. N Engl J Med 2009, 361:2221-2229.
4. Ashraf H, Dirksen A, Loft A, et al. Combined use of positron emission tomography and volume doubling time in lung cancer screening with low-dose CT scanning. Thorax 2011, 66:315-319.
5. Cronin P, Dwamena BA, Kelly AM, Bernstein SJ, Carlos RC Solitary pulmonary nodules and masses: a meta-analysis of the diagnostic utility of alternative imaging tests. Eur Radiol 2008, 18:1840-1856.
6. Baldwin DR, Duffy SW, Wald NJ, Page R, Hansell DM, Field JK UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer. Thorax 2011, 66:308-313.
7. Couraud S, Cortot AB, Greillier L, et al. From randomised trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the French intergroup (IFCT) and the groupe d'Oncologie de langue francaise (GOLF). Ann Oncol 2013, 24:586-597.
8. Wiener RS, Schwartz LM, Woloshin S, Welch HG Population-based risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge records. Ann Intern Med 2011, 155:137-144.
9. LaPar D, Bhamidipati C, Lau C, Jones D, Kozower B The Society of Thoracic Surgeons General Thoracic Surgery Database: establishing generalisability to national lung cancer resection outcomes. Ann Thorac Surg 2012, 94:216-221.
10. Haasbeek C, Palma D, Visser O, Lagerwaard F, Slotman B, Senan S Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands. Ann Oncol 2012, 23:2743-2747.
11. Senthi S, Lagerwaard F, Haasbeek C, Slotman B, Senan S Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol 2012, 13:802-809.
12. Palma DA, Senan S Early-stage non-small cell lung cancer in elderly patients: should stereotactic radiation therapy be the standard of care?. Int J Radiat Oncol Biol Phys 2012, 84:1058-1059.
13. Lagerwaard F, Verstegen N, Haasbeek C, et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2012, 83:348-353.
14. Onishi H, Shirato H, Nagata Y, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery?. Int J Radiat Oncol Biol Phys 2011, 81:1352-1358.
15. 18F-fluorodeoxyglucose-positron emission tomography scan in the Nederlands Leuvens Longkanker screenings Onderzoek lung cancer screening trial. J Thorac Oncol 2011, 6:1704-1712.
16. Deppen S, Putnam JB, Andrade G, et al. Accuracy of FDG-PET to diagnose lung cancer in a region of endemic granulomatous disease. Ann Thorac Surg 2011, 92:428-432.
17. Wallace M, Kristhnamurthy S, Broemeling L, et al. CT-guided percutaneous fine-needle aspiration biopsy of small (< or =1-cm) pulmonary lesions. Radiology 2002, 225:823-828.
18. Gelbman B, Cham M, Kim W, et al. Radiographic and clinical characterization of false negative results from CT-guided needle biopsies of lung nodules. J Thorac Oncol 2012, 7:815-820.
19. Zaman M, Bilal H, Woo CY, Tang A In patients undergoing video-assisted thoracoscopic surgery excision, what is the best way to locate a subcentimetre solitary pulmonary nodule in order to achieve successful excision?. Interact Cardiovasc Thorac Surg 2012, 15:266-272.
20. Ginsberg RJ, Rubinstein LV Randomized trial of lobectomy versus limited resection for T1N0 non-small cell lung cancer. Ann Thorac Surg 1995, 60:615-622. for the Lung Cancer Study Group.
21. Donington JS Point: are limited resections appropriate in non-small cell lung cancer? Yes. Chest 2012, 141:588-590.
22. Stiles BM, Altorki NK Segementectomy versus lobectomy for stage I lung cancer in patients with good pulmonary function. Difficult decisions in thoracic surgery 2011, 125-133. Springer-Verlag, London. 2nd ed. M.K. Ferguson (Ed.).
23. Dahele M, Palma D, Lagerwaard F, Slotman B, Senan S Radiological changes after stereotactic radiotherapy for stage I lung cancer. J Thorac Oncol 2011, 6:1221-1228.
24. Neri S, Takahashi Y, Terashi T, et al. Surgical treatment of local recurrence after stereotactic body radiotherapy for primary and metastatic lung cancers. J Thorac Oncol 2010, 5:2003-2007.
25. Chen F, Matsuo Y, Yoshizawa A, et al. Salvage lung resection for non-small cell lung cancer after stereotactic body radiotherapy in initially operable patients. J Thorac Oncol 2010, 5:1999-2002.
26. Allibhai Z, Cho BC, Taremi M, et al. Surgical salvage following stereotactic body radiotherapy for early-stage NSCLC. Eur Respir J 2012, 39:1039-1042.
27. Bongers E, Haasbeek C, Lagerwaard F, Slotman B, Senan S Incidence and risk factors for chest wall toxicity after risk-adapted stereotactic radiotherapy for early-stage lung cancer. J Thorac Oncol 2011, 6:2052-2057.
28. Palma DA, Senan S Improving outcomes for high-risk patients with early-stage non-small-cell lung cancer: insights from population-based data and the role of stereotactic ablative radiotherapy. Clin Lung Cancer 2013, 14:1-5.
29. Lagerwaard F, Haasbeek C, Smit E, Slotman B, Senan S Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008, 70:685-692.
30. Shirvani S, Jiang J, Chang J, et al. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys 2012, 84:1060-1070.
31. Palma D, Lagerwaard F, Rodrigues G, Haasbeek C, Senan S Curative treatment of stage I non-small-cell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review. Int J Radiat Oncol Biol Phys 2012, 82:1149-1156.
32. Crabtree T, Puri V, Timmerman R, et al. Treatment of stage I lung cancer in high-risk and inoperable patients: comparison of prospective clinical trials using stereotactic body radiotherapy (RTOG 0236), sublobar resection (ACOSOG Z4032), and radiofrequency ablation (ACOSOG Z4033). J Thorac Cardiovasc Surg 2013, 145:692-699.
33. van der Voort van Zyp NC, Prévost JB, van der Holt B, et al. Quality of life after stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2010, 77:31-37.
34. Lagerwaard FJ, Aaronson NK, Gundy CM, Haasbeek CJ, Slotman BJ, Senan S Patient-reported quality of life after stereotactic ablative radiotherapy for early-stage lung cancer. J Thorac Oncol 2012, 7:1148-1154.
35. Merrill RM, Hunter BD Conditional survival among cancer patients in the United States. Oncologist 2010, 15:873-882.
36. Janssen-Heijnen ML, van Steenbergen LN, Steyerberg E, et al. Long-term excess mortality for survivors of non-small cell lung cancer in the Netherlands. J Thorac Oncol 2012, 7:496-502.
37. Lou F, Huang J, Sima CS, Dycoco J, Rusch V, Bach PB Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance. J Thorac Cardiovasc Surg 2013, 145:75-81.
38. Surapaneni R, Singh P, Rajagopalan K, Hageboutros A Stage I lung cancer survivorship: risk of second malignancies and need for individualized care plan. J Thorac Oncol 2012, 7:1252-1256.
39. Jaklitsch MT, Jacobson FL, Austin JH, et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg 2012, 144:33-38.
40. Herder GJ, van Tinteren H, Golding RP, et al. Clinical prediction model to characterize pulmonary nodules: validation and added value of 18Ffluorodeoxyglucose positron emission tomography. Chest 2005, 128:2490-2496.
41. Wahidi MM, Govert JA, Goudar RK, Gould MK, McCrory DC Evidence for the treatment of patients with pulmonary nodules: when is it lung cancer? ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132(3 suppl):94S-107S. for the American College of Chest Physicians.
42. van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002, 359:1388-1392.
43. Herder GJ, Kramer H, Hoekstra OS, et al. Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol 2006, 24:1800-1806.
44. Verstegen NE, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease. Radiother Oncol 2011, 101:250-254.
45. Swensen SJ, Silverstein MD, Ilstrup DM, et al. The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules. Arch Intern Med 1997, 157:849-855.
46. Gould MK, Ananth L, Barnett PG A clinical model to estimate the pre-test probability of lung cancer in patients with solitary pulmonary nodules. Chest 2007, 131:383-388.
47. Veronesi G, Maisonneuve P, Pelosi G, et al. Screening-detected lung cancers: is systematic nodal dissection always essential?. J Thorac Oncol 2011, 6:525-530.
48. Felip E, Rosell R, Maestre JA, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol 2010, 28:3138-3145.
49. Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009, 114:589-595.
50. Formenti SC, Demaria S Radiation therapy to convert the tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys 2012, 84:879-880.
51. Saynak M, Veeramachaneni NK, Hubbs JL, et al. Local failure after complete resection of N0-1 non-small cell lung cancer. Lung Cancer 2011, 71:156-165.
52. Salzburg global seminar. BMJ 2011, 342:d1745. Salzburg statement on shared decision making.